share_log

RBC Capital Reiterates Outperform on Ultragenyx Pharmaceutical, Maintains $77 Price Target

Benzinga ·  Nov 6 12:00  · Ratings

RBC Capital analyst Luca Issi reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Outperform and maintains $77 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment